Efficacy of Captopril in Covid-19 Patients With Severe Acute Respiratory Syndrome (SARS) CoV-2 Pneumonia (CAPTOCOVID)

• Status: Not yet recruiting
• Trial end date: 2020-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Captopril being an effective drug available in liquid preparation, administration by nebulization could be of interest for maximizing lung action and minimizing systemic side effects. Such a treatment might be used for "Covid-19" patients with pneumonia in order to avoid ARDS.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assistance Publique - Hôpitaux de Paris
• Treatments: Captopril

Criteria

Inclusion Criteria:

1. Hospitalization for acute respiratory failure requiring oxygen administration ≥3L/mn

2. Age > 18 years or older

3. Presence of pneumonia

4. PCR SARS-CoV-2 positive in any biological sample in the last 7 days

5. Patient affiliated to social security regime

6. Written informed consent provided by the patient or alternatively by next-of-kin, or in emergency situations, prior to any protocol-specific procedures

Exclusion Criteria:

1. Decision of withholding invasive mechanical ventilation

2. Shock requiring vasopressor infusion

3. Co-infection with another respiratory pathogen which could be responsible of pneumonia

4. Hypersensitivity to captopril, to any other angiotensin converting enzyme inhibitor or any of the excipients of the specialty used

5. History of angio-oedema

6. History of ACE-inhibitor allergy

7. Known pregnancy or current lactation: Female subject of childbearing potential should have a negative serum pregnancy test prior to receiving the first dose of study medication.

8. Patient who is currently enrolled in other investigational study;

9. Persons deprived of their liberty by judicial or administrative decision,

10. Persons under legal protection/safeguard of justice,

11. Patients under duress psychiatric care,

12. Persons admitted to a health or social institution

13. Patient on state medical aid